Incobotulinum Toxin A with a One-year Long-lasting Effect for Trapezius Contouring and Superior Efficacy for the Treatment of Trapezius Myalgia

Napamon Supornpun; Paisal Rummaneethorn; Thamthiwat Nararatwanchai; Tawee Saiwichai; Sirinthip Chaichalotornkul

doi:10.4103/JCAS.JCAS_68_21

Incobotulinum Toxin A with a One-year Long-lasting Effect for Trapezius Contouring and Superior Efficacy for the Treatment of Trapezius Myalgia

J Cutan Aesthet Surg. 2022 Apr-Jun;15(2):168-174. doi: 10.4103/JCAS.JCAS_68_21.

Authors

Napamon Supornpun¹, Paisal Rummaneethorn¹, Thamthiwat Nararatwanchai¹, Tawee Saiwichai², Sirinthip Chaichalotornkul¹

Affiliations

¹ School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok, Thailand.
² Faculty of Public Health, Mahidol University, Bangkok, Thailand.

Abstract

Context: Based on various Botulinum toxin A products, reports of the lower efficacy of Incobotulinum toxin A compared with Onabotulinum toxin A for muscle contouring were observed. In addition, complications of trapezius myalgia and shoulder contouring treatment from malpractice have been reported.

Aims: The study aimed at comparing the efficacy between Incobotulinum toxin A and Onabotulinum toxin A; research was conducted on a safe treatment technique for trapezius hypertrophy and trapezius myalgia.

Materials and methods: A split-shoulder, double-blind, randomized controlled trial was performed. Twenty volunteers with trapezius hypertrophy and trapezius myalgia were randomly injected with 30 units of Incobotulinum toxin A and Onabotulinum toxin A in each trapezius muscle guided by ultrasound.

Results: The trapezius thickness among those receiving treatment with Onabotulinum toxin A and Incobotulinum toxin A on day 60 was 7.35 ± 1.11 and 7.33 ± 1.21 mm, respectively, which did not portray a significant difference (P = 0.991). Compared with the muscle size from day 60 to one year, the size of the trapezius muscle that had been treated by Onabotulinum toxin type A regained a significantly larger size compared with that treated by Incobotulinum toxin A (P = 0.027). On comparing the size of the trapezius muscle treated by Incobotulinum toxin A between one year and day 0, it was observed that the trapezius thickness at one year had significantly decreased (P < 0.001). On comparing the pain score from day 60 to day 0, it was observed that the pain scores of trapezius myalgia treated by Onabotulinum toxin A and Incobotulinum toxin A significantly differed (P = 0.003).

Conclusions: Incobotulinum toxin A had the same efficacy but a longer lasting effect for the trapezius size contouring and a higher efficacy for trapezius myalgia treatment compared with Onabotulinum toxin A.

Keywords: Incobotulinum toxin A; Onabotulinum toxin A; trapezius hypertrophy; trapezius myalgia; ultrasound-guided injection.